ObsEva SA (NASDAQ: OBSV) has disclosed today that it has submitted the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA). The firm has submitted the application for YSELTY for the treatment of uterine fibroids. ObsEva is anticipating to launch the YSELTY in
